<DOC>
	<DOCNO>NCT00613431</DOCNO>
	<brief_summary>The main purpose study assess safety measure pharmacokinetics CS-8080 healthy volunteer .</brief_summary>
	<brief_title>Effects CS-8080 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Healthy men and/or woman , age 18 45 year inclusive . Women must nonchild bear potential , ie , either : Surgically sterile ( ie , bilateral tubal ligation removal ovary and/or uterus least 6 month prior dose ) , Naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose , FSH level screen &gt; 40 mIU/mL . All woman must negative serum pregnancy test screening within 48 hour dose . Body Mass Index ( BMI ) 19 30 kg/m2 inclusive . Good health determine absence clinically significant deviation normal , base medical history , physical examination , laboratory report , 12 lead ECG , deem Investigator , prior enrollment . Able understand willing comply study requirement , willing follow study medication regimen . Willing able give write informed consent . Negative urine test drug abuse alcohol screening checkin . Negative result HIV antibody , hepatitis B surface antigen , hepatitis C antibody screen . Exclusion Criteria Any history drug abuse . History alcohol addiction 2 year prior Day 1 . History significant allergic response drug except penicillin . History current evidence , determine Investigator , psychiatric emotional problem would invalidate give informed consent limit ability subject comply study requirement . History current evidence clinically significant cardiac , hepatic , renal , pulmonary , endocrine , neurologic , infectious , gastrointestinal ( ie , condition may affect drug absorption ) , hematologic , oncologic disease determine Investigator review screen history , physical examination , laboratory test result , 12lead ECG . History current alcoholic nonalcoholic liver disease liver steatosis . History prostate disease prostatitis . Subjects history congenital Long QT Syndrome ( LQTS ) , history survive neardrowning episode , history form syncope loss consciousness . Subjects QTc interval duration &gt; 450 msec obtain average ECG machine reading triplicate ECG ( 3 reading rapid succession 2 minute apart ) take screening , least 10 minute quiet rest supine position . Subjects abnormal ECG waveform morphology ECGs screening triplicate would preclude accurate manual measurement QT interval duration . Need concomitant medication . Prestudy medication use specify Section 6.2.1 . Consumption food beverage contain grapefruit 7 day prior Day 1 study completion . Consumption food beverage contain alcohol 24 hour checkin discharge clinic . Blood donation significant blood loss within 56 day Day 1 . Plasma donation within 7 day Day 1 . Participation another investigational new drug research study within 30 day Day 1 . Use tobacco product nicotinecontaining product ( include smoke cessation aid , gum patch ) within 6 month Day 1 . Relationship subject Investigator , subinvestigator , pharmacist , study coordinator , staff directly involve conduct study , employment Sponsor contract research organization participate study . Screening laboratory value outside range normal value deem clinically significant Investigator . Serum lipid test , triglyceride , cholesterol ( LDL , HDL total cholesterol ) , liver function test ( ALT , AST , GGT , total bilirubin , LDH ALP ) PSA must exceed upper limit normal without permission Sponsor . Hemoglobin &lt; 12.0 g/dL screen visit . Shift work , defined work shift , either regular irregular , preclude sleep hour 10 pm 6 , within 1 week prior Day 2 , 2 work shift per week meeting criterion 4 1 week prior Day 2 . Positive fecal occult blood test screening . Familial relationship study participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>pharmacodynamics</keyword>
</DOC>